File Download
  Links for fulltext
     (May Require Subscription)

Conference Paper: The impact of complete metabolic response in the treatment of metastatic colorectal cancer

TitleThe impact of complete metabolic response in the treatment of metastatic colorectal cancer
Authors
KeywordsMedical sciences
Oncology
Issue Date2014
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
The 39th European Society for Medical Oncologist Congress (ESMO 2014), Madrid, Spain, 26-30 September 2014. In Annals of Oncology, 2014, v. 25 suppl. 4, p. iv203, abstract no. 595P How to Cite?
AbstractAIM: Molecular imaging with 18F-FDG PET scan is increasingly used for monitoring of treatment response in metastatic colorectal cancer. While there is no widely accepted standard for defining partial response, metabolic complete response (mCR) appears as a more reproducible endpoint.We performed a retrospective study to evaluate the impact of mCR on both treatment outcomes and treatment plan. METHODS: Patients who were referred to our department for further management of colorectal cancer from Jan 2008 to Dec 2011 were retrospectively reviewed. They were included for subsequent analysis if [1] achieved mCR on 18F-FDG PET scan during first-line therapy, [2] serial PET scans (>= 2) available for demonstration of change in 18F-FDG avidity. The primary endpoint was progression-free survival (PFS). Secondary endpoint were overall survival (OS), time-to-mCR (TTm) and impact ofmCR on subsequent treatment plan. RESULTS: Among the 1007 patients referred to us, 356 patients (35%) received systemic therapy for metastatic disease and 202 of them (20%) had PET scan done during the course of systemic therapy. Forty-three patients achieved mCR and 37 of them fulfilled all the criteria for subsequent analysis. mCR was achieved after a median of 4 cycles of systemic therapy (Range 3-12 cycles) after a median TTm of 14weeks (95% CI 12.5-15.5). Subsequent treatment was not altered in 21 patients (56.7%) who had planned drug holiday after six months of therapy. Six and ten of the remaining patients received maintenance therapy and consolidation treatment (resection or radiotherapy), respectively. After a median follow up time of 33 months, the median PFS and OS was 14.4 months (95% CI 10.3 to 18.6) and 47.1 months (95% CI 36.8 to 57.4), respectively. Normal initial CEA (<5ng/ml) was significant predictor of prolonged PFS on both univariate and multivariate analysis (p = 0.05; HR 3.49, 95% CI 1.45–8.37). Liver-onlymetastasis, Kras mutation status, use of any target therapy or coexisting radiological complete response were not significant predictor of survival in patients who achieved mCR. CONCLUSIONS: Favorable outcomes were observed in patients who achieved mCR on 18F-FDG PET scan. Its current impact on treatment decision remains elusive and further studies warranted.
DescriptionThis journal suppl. entitled: Abstract Book of the 39th ESMO Congress (ESMO 2014) Madrid, Spain 26-30 September 2014
Session - Gastrointestinal tumours, colorectal: no. 595P
Persistent Identifierhttp://hdl.handle.net/10722/204423
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorLam, KOen_US
dc.contributor.authorCheung, Gen_US
dc.contributor.authorSze, HCKen_US
dc.contributor.authorLee, VHen_US
dc.contributor.authorTsang, Jen_US
dc.contributor.authorChoy, TSen_US
dc.contributor.authorLeung, TWen_US
dc.contributor.authorKwong, DLWen_US
dc.date.accessioned2014-09-19T23:45:34Z-
dc.date.available2014-09-19T23:45:34Z-
dc.date.issued2014en_US
dc.identifier.citationThe 39th European Society for Medical Oncologist Congress (ESMO 2014), Madrid, Spain, 26-30 September 2014. In Annals of Oncology, 2014, v. 25 suppl. 4, p. iv203, abstract no. 595Pen_US
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/204423-
dc.descriptionThis journal suppl. entitled: Abstract Book of the 39th ESMO Congress (ESMO 2014) Madrid, Spain 26-30 September 2014-
dc.descriptionSession - Gastrointestinal tumours, colorectal: no. 595P-
dc.description.abstractAIM: Molecular imaging with 18F-FDG PET scan is increasingly used for monitoring of treatment response in metastatic colorectal cancer. While there is no widely accepted standard for defining partial response, metabolic complete response (mCR) appears as a more reproducible endpoint.We performed a retrospective study to evaluate the impact of mCR on both treatment outcomes and treatment plan. METHODS: Patients who were referred to our department for further management of colorectal cancer from Jan 2008 to Dec 2011 were retrospectively reviewed. They were included for subsequent analysis if [1] achieved mCR on 18F-FDG PET scan during first-line therapy, [2] serial PET scans (>= 2) available for demonstration of change in 18F-FDG avidity. The primary endpoint was progression-free survival (PFS). Secondary endpoint were overall survival (OS), time-to-mCR (TTm) and impact ofmCR on subsequent treatment plan. RESULTS: Among the 1007 patients referred to us, 356 patients (35%) received systemic therapy for metastatic disease and 202 of them (20%) had PET scan done during the course of systemic therapy. Forty-three patients achieved mCR and 37 of them fulfilled all the criteria for subsequent analysis. mCR was achieved after a median of 4 cycles of systemic therapy (Range 3-12 cycles) after a median TTm of 14weeks (95% CI 12.5-15.5). Subsequent treatment was not altered in 21 patients (56.7%) who had planned drug holiday after six months of therapy. Six and ten of the remaining patients received maintenance therapy and consolidation treatment (resection or radiotherapy), respectively. After a median follow up time of 33 months, the median PFS and OS was 14.4 months (95% CI 10.3 to 18.6) and 47.1 months (95% CI 36.8 to 57.4), respectively. Normal initial CEA (<5ng/ml) was significant predictor of prolonged PFS on both univariate and multivariate analysis (p = 0.05; HR 3.49, 95% CI 1.45–8.37). Liver-onlymetastasis, Kras mutation status, use of any target therapy or coexisting radiological complete response were not significant predictor of survival in patients who achieved mCR. CONCLUSIONS: Favorable outcomes were observed in patients who achieved mCR on 18F-FDG PET scan. Its current impact on treatment decision remains elusive and further studies warranted.-
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/-
dc.relation.ispartofAnnals of Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology-
dc.titleThe impact of complete metabolic response in the treatment of metastatic colorectal canceren_US
dc.typeConference_Paperen_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.emailSze, HCK: henrysze@graduate.hku.hken_US
dc.identifier.emailLee, VH: vhflee@hku.hken_US
dc.identifier.emailTsang, J: jwhtsang@hku.hken_US
dc.identifier.emailChoy, TS: choyts@hku.hken_US
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hken_US
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.authoritySze, HCK=rp01697en_US
dc.identifier.authorityLee, VH=rp00264en_US
dc.identifier.authorityTsang, J=rp00278en_US
dc.identifier.authorityKwong, DLW=rp00414en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/annonc/mdu333.97-
dc.identifier.hkuros236311en_US
dc.identifier.volume25-
dc.identifier.issuesuppl. 4-
dc.identifier.spageiv203, abstract no. 595P-
dc.identifier.epageiv203, abstract no. 595P-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats